Financials (USD)
Sales 2024 * | 510M | Sales 2025 * | 642M | Capitalization | 2.98B |
---|---|---|---|---|---|
Net income 2024 * | -65M | Net income 2025 * | 65M | EV / Sales 2024 * | 6.19 x |
Net Debt 2024 * | 182M | Net Debt 2025 * | 84.17M | EV / Sales 2025 * | 4.77 x |
P/E ratio 2024 * |
-46.7
x | P/E ratio 2025 * |
47.9
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.81% |
Latest transcript on Amicus Therapeutics
Managers | Title | Age | Since |
---|---|---|---|
Bradley Campbell
CEO | Chief Executive Officer | 48 | 06-03-31 |
Simon Harford
DFI | Director of Finance/CFO | 63 | 23-08-20 |
Pat O’Sullivan
COO | Chief Operating Officer | - | 22-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bradley Campbell
CEO | Chief Executive Officer | 48 | 06-03-31 |
Lynn Bleil
BRD | Director/Board Member | 60 | 18-09-10 |
Burke Whitman
BRD | Director/Board Member | 68 | 19-06-26 |
1st Jan change | Capi. | |
---|---|---|
+48.93% | 56.95B | |
+39.24% | 40.26B | |
-7.52% | 39.32B | |
-5.96% | 28.37B | |
+14.25% | 26.45B | |
-19.94% | 19.41B | |
+32.32% | 12.54B | |
+24.40% | 12.21B | |
-0.21% | 12.15B |